I4P Stock Overview Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Intercept Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Intercept Pharmaceuticals Historical stock prices Current Share Price US$17.52 52 Week High US$19.97 52 Week Low US$8.16 Beta 0.88 1 Month Change 0.46% 3 Month Change 90.52% 1 Year Change 14.92% 3 Year Change -45.23% 5 Year Change -79.17% Change since IPO 17.29%
Recent News & Updates
Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA) Nov 13
Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA Oct 17
Intercept Announces Statement on FDA Advisory Committee Meeting Sep 16
Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024 Jun 06
Intercept Pharmaceuticals, Inc. Files Form 15 Nov 21
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023 Nov 15 See more updates
Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA) Nov 13
Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA Oct 17
Intercept Announces Statement on FDA Advisory Committee Meeting Sep 16
Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024 Jun 06
Intercept Pharmaceuticals, Inc. Files Form 15 Nov 21
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023 Nov 15
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023 Nov 14
Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023 Nov 11 Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).
Third quarter 2023 earnings released: US$0.066 loss per share (vs US$3.04 loss in 3Q 2022) Nov 07
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors Oct 24 Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million. Sep 27
Now 22% undervalued after recent price drop Sep 06
Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.68 loss in 2Q 2022) Aug 03
Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023 Aug 03
Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage Jun 23
Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023 Jun 08
Forecast breakeven date moved forward to 2024 May 01
First quarter 2023 earnings released: US$0.77 loss per share (vs US$1.13 loss in 1Q 2022) Apr 28 Apr 27
Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021) Mar 03
U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash Jan 20
Forecast breakeven date pushed back to 2025 Dec 31
Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH Dec 24 Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 Nov 07
Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021) Nov 02
Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 26
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint Oct 01
Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology Sep 21
Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021) Aug 04
Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 28
Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022 Jul 27
Forecast to breakeven in 2022 Jul 08
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) Jul 08
Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline Jun 07 Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance
Forecast to breakeven in 2024 May 12
Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis May 12
Forecast breakeven date moved forward to 2022 May 09
First quarter 2022 earnings released: US$0.58 loss per share (vs US$1.22 loss in 1Q 2021) May 07 Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022
Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022 Mar 04
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 03
Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022 Mar 03
Intercept Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022 Feb 25
Pomerantz Law Firm Announces the Filing of A Class Action Against Intercept Pharmaceuticals, Inc Jan 07
Forecast to breakeven in 2024 Jan 01
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH Dec 21
Intercept Pharmaceuticals, Inc. Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH Dec 10
Third quarter 2021 earnings released: US$0.11 loss per share (vs US$2.02 loss in 3Q 2020) Nov 04
Intercept Pharmaceuticals, Inc. announced a financing transaction Aug 12
Second quarter 2021 earnings released: US$0.33 loss per share (vs US$1.92 loss in 2Q 2020) Jul 31
Intercept Pharmaceuticals, Inc. to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021 Jun 22
Independent Director Daniel Welch has left the company Jun 09
Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2021 May 07
First quarter 2021 earnings released: US$1.22 loss per share (vs US$2.86 loss in 1Q 2020) May 07
CFO, Treasurer & Principal Accounting Officer has left the company Mar 30 Intercept Pharmaceuticals, Inc. Appoints Rocco Venezia as Chief Accounting Officer
Chief Medical Officer has left the company Mar 07
New 90-day low: €19.65 Feb 26
Full year 2020 earnings released: US$8.34 loss per share (vs US$10.89 loss in FY 2019) Feb 26
Revenue misses expectations Feb 26 Intercept Pharmaceuticals, Inc. Appoints Dagmar Rosa-Bjorkeson to its Board of Directors
Intercept Pharmaceuticals, Inc. Announces Management Changes Feb 18
Intercept Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 12
Intercept Pharmaceuticals, Inc. Announces Resignation of Richard Kim as President, U.S. Commercial & Strategic Marketing, Effective February 15, 2021 Jan 22
Intercept Pharmaceuticals, Inc. Appoints Jared M. Freedberg as General Counsel and Secretary Jan 12
Rosen Law Firm Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action Dec 25
Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers – ICPT Dec 22
New 90-day low: €22.54 Dec 22
Intercept Pharmaceuticals, Inc. Announces Leadership Transition Dec 11
Rosen Law Firm Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action Dec 10
Intercept Pharmaceuticals, Inc. Announces Resignation of Ryan T. Sullivan as General Counsel and Secretary, Effective December 11, 2020 Nov 18
Intercept Pharmaceuticals, Inc. Announces New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in A Subgroup of High-Risk Patients with Fibrosis Due to NASH Nov 17
Revenue beats expectations Nov 11
Third quarter 2020 earnings released: US$2.02 loss per share Nov 11
Intercept Pharmaceuticals, Inc. Announces Sales Guidance 2020 Nov 10
Bragar Eagel & Squire, P.C. Files Lawsuit Against Intercept Pharmaceuticals, Inc Nov 06
Intercept Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 09, 2020 Nov 05
New 90-day low: €24.06 Oct 26
New 90-day low: €31.22 Oct 10 Shareholder Returns I4P DE Biotechs DE Market 7D -0.8% -0.8% -1.6% 1Y 14.9% -13.0% 6.8%
See full shareholder returns
Return vs Market: I4P exceeded the German Market which returned 5.9% over the past year.
Price Volatility Is I4P's price volatile compared to industry and market? I4P volatility I4P Average Weekly Movement 22.8% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: I4P's share price has been volatile over the past 3 months.
Volatility Over Time: I4P's weekly volatility has increased from 15% to 23% over the past year.
About the Company Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development.
Show more Intercept Pharmaceuticals, Inc. Fundamentals Summary How do Intercept Pharmaceuticals's earnings and revenue compare to its market cap? I4P fundamental statistics Market cap €742.08m Earnings (TTM ) -€53.66m Revenue (TTM ) €296.65m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) I4P income statement (TTM ) Revenue US$317.68m Cost of Revenue US$632.00k Gross Profit US$317.05m Other Expenses US$374.52m Earnings -US$57.47m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -1.37 Gross Margin 99.80% Net Profit Margin -18.09% Debt/Equity Ratio 311.6%
How did I4P perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/11/09 14:13 End of Day Share Price 2023/11/07 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Intercept Pharmaceuticals, Inc. is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Birchenough BMO Capital Markets Equity Research Geoffrey Meacham BofA Global Research Mayank Mamtani B. Riley Securities, Inc.
Show 25 more analysts 
